Three separate studies point to ways of attacking bacterial survival and aggression: disrupting energy production in Mycobacterium abscessus, anticipating how it changes to evade bacteriophages, and blocking the toxin-loading machinery of Pseudomonas aeruginosa. These are research findings—not one combined treatment, and none establishes clinical benefit for patients.
Three vulnerabilities, two pathogens
The studies address different biological problems. One tests an experimental inhibitor of an energy-producing enzyme in M. abscessus. Another examines how the same bacterium can resist viruses that infect bacteria. A third maps how P. aeruginosa loads toxins into a weapon it uses against other cells.
As an Amazon Associate I earn from qualifying purchases.
| Research strand | Pathogen | Vulnerability examined | Evidence described in institutional reports |
|---|---|---|---|
| Energy production | M. abscessus | Cytochrome bcc:aa3 oxidase in the electron transport chain | Experimental inhibitor ND-011458, including a reported combination experiment with clofazimine (NTU, October 3, 2026) |
| Phage resistance | M. abscessus | Surface changes that can prevent phage binding | Morphotype switching and other surface-related mutations; a multi-phage approach outperformed single-phage treatment in the study context (A*STAR, May 4, 2026) |
| Toxin loading | P. aeruginosa | Hcp-mediated assembly of toxin cargo for the type VI secretion system | Structural and mechanistic study of how toxins are captured and loaded before the system fires (NTU, October 3, 2026) |
How an experimental inhibitor targets M. abscessus‘s energy supply
M. abscessus can cause severe lung disease, including in people with cystic fibrosis, and is intrinsically resistant to many commonly used antibiotics. The NTU-reported study led by professor Gerhard Grüber focused on cytochrome bcc:aa3 oxidase, part of the bacterium’s electron transport chain. That chain helps produce ATP, the energy source for essential cellular processes.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitchesFrom enzyme structure to candidate compound
Using cryo-electron microscopy, the researchers identified a substrate-binding pocket in the enzyme’s cytochrome b subunit and designed ND-011458 to fit the pocket and inhibit the oxidase. The rationale is to undermine energy production—and potentially processes that help the bacterium withstand antibiotics—rather than to attack only a conventional antibiotic target.
#1 Best Overall
What the combination result does and does not show
NTU’s October 3, 2026 report says ND-011458 used with clofazimine reduced M. abscessus by two logs in four days in the reported experiment. That is an experimental result, not a patient outcome, an approved regimen or evidence of clinical efficacy. The report says a patent was filed and researchers were working with U.S.-based Hsiri Therapeutics on licensing; it does not establish the compound’s current clinical-trial status, availability or the present status of that licensing work.
The paper is Vikneswaran Mathiyazakan et al., “The Mycobacterium abscessus cytochrome bcc:aa3 oxidase structure paves the way for an agent targeting subunit QcrB,” Nature Communications (2026), DOI 10.1038/s41467-026-70805-5. The study summary and result figures here are reported by NTU.
Rank #2
How M. abscessus can change to resist bacteriophages
Bacteriophages, or phages, are viruses that infect bacteria. Phage treatment therefore faces an evolutionary problem: bacteria that survive exposure may carry changes that make them harder for the virus to recognize or infect.
Smooth-to-rough switching can change the bacterial surface
According to NTU and A*STAR accounts of the study, smooth M. abscessus strains produce glycopeptidolipids on their surfaces. Under phage pressure, some bacteria shifted to a rough form associated with mutations in genes needed to make or transport those lipids. The researchers hypothesize that losing the lipids can prevent phage binding. Other bacteria resisted phages while staying smooth, through mutations in different surface-related genes.
Rank #3
This means resistance is not limited to one visible switch: both morphotype changes and other surface alterations may matter. The study’s design implication is to target smooth bacteria while also accounting for rough variants emerging under phage pressure. A*STAR reported that this combination approach performed better than single-phage treatment in the study context; that finding does not establish a generally effective patient therapy.
The study is Jun Hao Liew et al., “Smooth-to-rough morphotype switching, a mechanism of phage resistance in Mycobacterium abscessus,” Proceedings of the National Academy of Sciences (2026), DOI 10.1073/pnas.2531197123. A*STAR’s account is dated May 4, 2026.
Rank #4
How P. aeruginosa loads toxins into its secretion system
The type VI secretion system (T6SS) is a contractile apparatus that bacteria use to inject toxins into other cells. In the study summarized by NTU, toxin loading is an organized assembly process rather than a single toxin simply being fired from the apparatus.
Free tools Windows power users keep installed
One-click scans. No signup required.
Hcp proteins capture and package toxin cargo
- Hcp proteins first capture toxin cargo.
- Five additional Hcp proteins wrap around the captured cargo to form a ring. A larger toxin may require two rings.
- Loaded rings stack to form a tube.
- When the secretion system contracts, it propels the tube outward, delivering its cargo. The tube can carry different toxins, so one firing can deliver more than one effector.
NTU research director and co-corresponding author Alain Filloux described the system as loading “a cocktail of toxins into a microscopic speargun” that can attack other bacteria, including beneficial bacteria, as well as host defense cells. The work’s structural detail helps explain how that toxin delivery is assembled; it does not show that a way to block the system is already available.
Best Value
The authors discuss two possible future directions: disrupting toxin loading to disarm the T6SS, or engineering harmless bacteria to carry T6SS cargo against invading bacteria. Both are prospective ideas, not demonstrated clinical interventions. The paper is Patricia Paracuellos et al., “Molecular basis of type VI secretion system effector loading,” Nature Microbiology (2026), DOI 10.1038/s41564-026-02363-x. NTU’s October 3, 2026 report summarizes the study.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What these findings mean for resistant infections
The shared lesson is that bacterial vulnerabilities may lie in supporting machinery as well as in the bacterium’s core survival. Energy production can be targeted; phage strategies need to anticipate bacterial adaptation; and a toxin-delivery apparatus may offer a point at which to interfere with attack. But these are distinct research paths with different evidence, not interchangeable treatment options.
- Energy metabolism: ND-011458 is an experimental inhibitor, and its reported result with clofazimine comes from an experiment rather than a clinical study.
- Phage adaptation: the M. abscessus findings identify routes to resistance and support considering both smooth bacteria and rough variants in phage strategies.
- Toxin delivery: the T6SS work describes a molecular loading mechanism that could inform future efforts to disarm it.
NTU’s report says the journal pages for the two Nature papers were not accessible to its account; the summaries above therefore reflect the institutional reporting, alongside A*STAR’s account of the phage work. No patient efficacy, independent replication or current clinical availability is established in these reports.
Recommended Free Tools
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
